Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SRPK2 antisense RNA 1 (SRPK2-AS1) is a long non-coding RNA transcribed from the locus antisense to the SRPK2 gene. Antisense RNAs in general can regulate the expression of their associated sense genes, often at the level of RNA stability, translation, or splicing, but specific functions for SRPK2-AS1 have not yet been described in the literature. No evidence currently supports its use as a direct therapeutic target. The inclusion of “antisense RNA 1” in the target name indicates it is a type of long non-coding RNA and not a protein, receptor, or customary "therapeutic target" class. As of the current literature and available genetic databases, there is scarce or no functional or disease association information for "SRPK2-AS1" specifically. Long non-coding antisense RNAs in general may play regulatory roles, but unless specific experimental evidence is available, it should not be classified as a traditional pharmacological target.
Not established; as a non-coding RNA, any mechanism would likely involve regulation of SRPK2 mRNA by RNA-RNA interaction or transcriptional interference
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SRPK2 antisense RNA 1 (SRPK2-AS1).